Interferon: Current status and future prospects in cancer therapy

Journal of Interferon and Cytokine Research

Volumn 31, Issue 7, 2011, Pages 545-552

  Wang, Ben X ^a   Rahbar, Ramtin ^a   Fish, Eleanor N ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; INTERFERON; INTERLEUKIN 2;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CELL ACTIVATION; CHRONIC MYELOID LEUKEMIA; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EVIDENCE BASED MEDICINE; GLIOMA; HAIRY CELL LEUKEMIA; HUMAN; IMMUNE RESPONSE; INTERFERON INDUCTION; KAPOSI SARCOMA; KIDNEY CARCINOMA; LEUKEMIA; MELANOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; DRUG RESISTANCE; DRUG THERAPY; FEMALE; FORECASTING; HUMANS; INTERFERON TYPE I; LEUKEMIA; NEOPLASTIC STEM CELLS; STEM CELL NICHE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960116603     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2010.0158     Document Type: Review

References (86)

1. Agarwala SS, Neuberg D, Park Y, Kirkwood JM. 2004. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observationnad BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer 100(8):1692-1698. (Pubitemid 38456347)
2. Agrawal M, Garg RJ, Kantarjian H, Cortes J. 2010. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy? Curr Oncol Rep 15(5):302-313.
3. Ahtiainen L, Mirantes C, Jahkola T, Escutenaire S, Diaconu I, Osterlund P, Kanerva A, Cerullo V, Hemminiki A. 2010. Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus. PLoS ONE 5(11): e13859.
4. Akaza H, Kawai K, Tsukamoto T, Fujioka T, Tomita Y, Kitamura T, Ozono S, Miki T, Naito S, Zembutsu H, Nakamura Y. 2010. Successful outcomes using combination therapy of interleukin-2 and interferon-alpha for renal cell carcinoma patients with lung metastasis. Jpn J Clin Oncol 40(7):684-689.
5. Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, Bernasconi P,Mancini M, Donti E, Grignani F, and others. 1990. Interferon alpha-2b as therapy for patients with Ph-positive chronic myelogenous leukemia. Eur J Haematol Suppl 52:25-28. (Pubitemid 20375385)
6. Allan NC, Richards SM, Shepherd PC. 1995. UK Medical Research Council randomised, multicentre trial of interferonalpha n1 for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. The UK Medical Research Councils Working Parties for Therapeutic Trials in Adult Leukemia. Lancet 345(8962):1392-1397.
7. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlander N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK. eds. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute Bethesda, MD. Available at http://seer.cancer.gov/csr/1975-2007/, based on November 2009 SEER data submission, posted on SEER website: 2010.
8. Ather MH, Masood N, Siddiqui T. 2010. Current management of advanced metastatic renal cell carcinoma. Urol J 7(1):1-9.
9. Atkins MB. 2006. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 12(7 Pt 2):2353s- 2358s.
10. Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM; Eastern Cooperative Oncology Group. 2008. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 26(35):5748-5754.
11. Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, Amabile M, Soverini S, Castagnetti F, Cilloni D, Izzo B, de Vivo A, Messa E, Bonifazi F, Poerio A, Luatti S, Giugliano E, Alberti D, Fincato G, Russo D, Pane F, Saglio G; GIMEMA Working Party on Chronic Myeloid Leukemia. 2004. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 104(13): 4245-4251. (Pubitemid 39620179)
12. Baldo P, Rupolo M, Compagnoni A, Lazzarini R, Bearz A, Cannizzaro R, Spazzapan S, Truccolo I,Moja L. 2010. Interferonalpha for maintenance of follicular lymphoma. Cochrane Database Syst Rev (1):CD004629.
13. Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim KB, Hwu WJ, McIntyre S, Rohlfs M, Homsi J, Hwu P. 2010. Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival? Melanoma Res. DOI: 10.1097/CMR.0b013e328341445f
14. Benz R, Stussi G, Fehr J. 2010. Interferon as an alternative to purine analogues in the treatment of hairy cell leukemia. Br J Haematol 148(4):664-665.
15. Boehm MD, Huang AJ. 2004. Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b. Ophthalmology 111(9):1755-1761. (Pubitemid 39179693)
16. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, Hehlmann R, Hochhaus A, Sheperd PC, Steegmann JL, Kluin-Nelemans HC, Thaler J, Simonsson B, Louwagie A, Reiffers J, Mahon FX, Montefusco E, Alimena G, Hasford J, Richards S, Saglio G, Testoni N, Martinelli G, Tura S, Baccarani M; Europena Study Group on Interferon in Chronic Myeloid Leukemia; Italian Cooperative Study Group on CML; France Intergroup of CML; German CML Study Group; UK Medical Research Council Working Party on CML; Spanish CML Study Group; Australian CML Study Group; Swedish CML Study Group. 2001. Chronic myeloid leukemia and interferonalpha: a study of complete cytogenetic responders. Blood 98(10):3074-3081.
17. Burchert A, Muller MC, Kostrewa P, Erben P, Bostel T, Liebler S, Hehlmann R, Neubauer A, Hochhaus A. 2010. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib pluas interferon alfa in patienst with chronic myeloid leukemia. J Clin Oncol 28(8): 1429-1435.
18. Burchert A, Wolfl S, Schmidt M, Brendel C, Denecke B, Cai D, Odyvanova L, Lahaye T, Muller MC, Berg T, Gschaidmeier H, Witting B, Hehlmann R, Hochhaus A, Neubauer A. 2003. Interferon-alpha, but not the ABL-kinas inhibitor imatinib (ST1571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 101(1): 259-264. (Pubitemid 36025916)
19. Cai T, Nesi G, Dal Canto M, Tinacci G, Mondaini N, Piazzini M, Geppetti P, Bartoletti R. 2010. Loss of heterozygosis on IFNalpha locus is a prognostic indicator of bacillus Calmette-Guerin response for nonmuscle invasive bladder cancer. J Urol 183(5):1738-1743.
20. Canil C, Hotte S, Mayhew LA, Waldon TS, Winquist E. 2010. Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: a systematic review. Can Urol Assoc J 4(3):201-208.
21. Cavalheiro S, Di Rocco C, Valenzuela S, Dastoli PA, Tamburrini G, Massimi L, Nicacio JM, Faquini IV, Ierardi DF, Silva NS, Pettorini BL, Toledo SR. 2010. Craniopharyngiomas: intratumoral chemptherapy with interferon-alpha: a multicenter preliminary study with 60 cases. Neurosurg Focus 28(4):E12.
22. Di Pucchio T, Pilla L, Capone I, Ferrantini M, Montefiore E, Urbani F, Patuzzo R, Pennacchioli E, Santinami M, Cova A, and others. 2006. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8() T cells and monocyte/dendritic cell precursors. Cancer Res 66(9): 4943-4951.
23. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. 1996. Effects of selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2(5):561-566.
24. Fernandez-Vozmediano JM, Armario-Hita JC. 2010. Treatment of basal cell carcinoma of the nasal pyramid with intralesional interferon alfa-2b. J Drugs Dermatol 9(4):381-384.
25. Galor A, Karp CL, Chhabra S, Barnes S, Alfonso EC. 2010. Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study. Br J Ophthalmol 94(5):551-554.
26. Garcia-Manero G, Faderl S, OBrien S, Cortes J, Talpaz M, Kantarjian HM. 2003. Chronic myelogenous leukemis: a review and update of therpeutic strategies. Cancer 98(3): 437-457. (Pubitemid 36885983)
27. Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WE, Cassileth PA, Habermann T, Golomb H, and others. 1995. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 13(4):974-982.
28. Groopman JE, Gottlieb MS, Goodman J, Mitsuyasu RT, Conant MA, Prince H, Fahey JL, Derezin M, Weinstein WM, Casavante C, and others. 1984. Recombinant alpha-2 interferon therapy for Kaposis sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 100(5):671-676. (Pubitemid 14143940)
29. Hasselbalch HC, Larsen TS, Riley CH, Jensen MK, Kiladjian JJ. 2010. Interferon alpha in the treatment of Philadelphia-negative chronic myeloprolioferative neoplasms. Status and perspectives. Curr Drug Targets PII: BSP/CDT/E-Pub/00205
30. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Loffler H, Hochhaus A, Heinze B, and others. 1994. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 84(12): 4064-4077. (Pubitemid 24371908)
31. Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Yao TJ, Oettgen HF, Livingston PO. 1995. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55(13):2783-2788.
32. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC. 2000. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 95(1):62-66. (Pubitemid 30017225)
33. Hoffman MA. 2010. Interferon-alpha is a very effective salvage therapy for patients with hairy cell leukemia relapsing after cladribine: a report of three cases. Med Oncol DOI: 10.1007/s12032-010-9550-z
34. Horoszewicz JS, Murphy GP. 1989. An assessment of the current use of human interferons in therapy of urological cancers. J Urol 142(5):1173-1180. (Pubitemid 19277937)
35. Ikeda K, Kobayashi M, Sekoo Y, Imai N, Hirakawa M, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. 2010. Administratio of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: a retrospective study of hepatitis C virus-related liver cancer. Hepatol Res 40(12):1168-1175.
36. Kantarjian HM, OBrien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S, Keating MJ, Freireich EJ, Talpaz M. 2003. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 97(4):1033-1041. (Pubitemid 36173155)
37. Kirkwood JM, Ibrahim JG, Sondak VK, Ernstoff MS, Ross M. 2002a. Interferon alfa-2a for melanoma metastases. Lancet 359(9310):978-979.
38. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH. 2000. Highand low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18(12):2444-2458. (Pubitemid 30415832)
39. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U. 2001. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19(9):2370-2380. (Pubitemid 32391207)
40. Kirkwood JM, Richards T, Zarour HM, Sosman J, Ernstoff M, Whiteside TL, Ibrahim J, Blum R, Wieand S, Mascari R. 2002b. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer 95(5):1101-1112. (Pubitemid 34925363)
41. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. 1996. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14(1):7-17. (Pubitemid 26019991)
42. Kokoschka EM, Trautinger F, Knobler RM, Pohl-Markl H, Micksche M. 1990. Long-term adjuvant therapy of high-risk malignant melanoma with interferon alpha 2b. J Invest Dermatol 95(6 Suppl):193S-197S.
43. Krown SE. 2007. AIDS-associated Kaposis sarcoma: is there still arole for interferon alfa? Cytokine Growth Factor Rev 18(5-6):395-402. (Pubitemid 47302825)
44. Kujawski LA, Talpaz M. 2007. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev 18(5-6):459-471. (Pubitemid 47302836)
45. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. 2003. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 138(10): 819-830. (Pubitemid 38124644)
46. Lansigan F, Foss FM. 2010. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 70(3):273-286.
47. Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G, and others. 1994. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12(5):1036-1044. (Pubitemid 24145334)
48. Lombardi G, Zustovich F, Donach M, Dalla Palma M, Nicoletto O, Pastorelli D. 2010. An update on targeted therapy in metastatic renal carcinoma. Urol Oncol DOI: 10.1016/j.urolonc.2009.12.018
49. Mackiewicz MM, Testori A, Trefzer U, Ferraresi V, Jassem J, Garbe C, Lesimple T, Guillot B, Gascon P, Gilde K, Camerini R, Cognetti F; Thymosin Melanoma Investigation Group. 2010. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with decarbazine in patients with metastatic melanoma. J Clin Oncol 28(10):1780-1787.
50. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, and others. 2005. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23(1):133-141. (Pubitemid 41702632)
51. Melichar B, Koralewski P, Ravaud A, Pluzanska A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Delva R, Sevin E, Negrier S, McKendrick J, Santoro A, Pisa P, Escudier B. 2008. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 19(8):1470-1476.
52. Mocellin S, Pasquali S, Rossi CR, Nitti D. 2010. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematicreview and meta-analysis. J Natl Cancer Inst 102(7):493-501.
53. Molto L, Alvarez-Mon M, Carballido J, Olivier C, Gimeno F, Manzano L. 1995. Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superfiical bladder cancer. Cancer 75(11):2720-2726.
54. Moschella F, Proietti E, Capone I, Belardelli F. 2010. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Ann NY Acad Sci 1194:169-178.
55. Motomura K, Natsume A, Kishida Y, Higashi H, Kondo Y, Nakasu Y, Abe T, Namba H, Wakai K, Wakabayashi T. 2010. Benefits of interferon- and temozolomide combination therapy for newly diagnozed primary glioblastoma with unmethylated MGMT promoter: a multicenter study. Cancer. DOI: 10.1002/cncr.25637
56. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M. 2000. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18(16):2972-2980. (Pubitemid 30644121)
57. Nakai N, Hartmann G, Kishimoto S, Katoh N. 2010. Dendritic cell vaccination in human melanoma: realtionships between clinical effects and vaccine parameters. Pigment Cell Melanoma Res 23(5):607-619.
58. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T. 1998. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais dImmunotherapie. N Engl J Med 338(18):1272-1278. (Pubitemid 28216581)
59. Niederle N, Kloke O, Wandl UB, Becher R, Moritz T, Opalka B. 1993. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies. Leuk Lymphoma 9(1-2):111-119. (Pubitemid 23141049)
60. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawaki S, Tsubaki K, and others. 1995. A randomized trial comparing interferonalpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86(3):906-916.
61. Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, Machiels JP, Baudard M, Ringeisen F, Velu T, Lefrere-Belda MA, Limacher JM, Fridman WH, Azizi M, Acres B, Tartour E. 2010. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother 60(2):261-271.
62. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, Arthur DD, Powell B, Gottlieb A, Peterson BA, Rai K, Testa JR, LeBeau M, Tantravahi R, Bloomfield CD. 1993. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 82(10):2975-2984. (Pubitemid 23334922)
63. Palandri F, Castagnetti F, Iacobucci I, Martinelli G, Amabile M, Gugliotta G, Poerio A, Testoni N, Breccia M, Bocchia M, Crugnola M, Rege-Cambrin G, Martino B, Pierri I, Radaelli F, Specchia G, Pane F, Saglio G, Rosti G, Baccarani M. 2010. The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Hematologica 95(8):1415-1419.
64. Parmar S, Platanias LC. 2005. Interferons. Cancer Treat Res 126:45-68.
65. Piro LD, Carrera CJ, Carson DA, Beutler E. 1990. Lasting remission in hairy-cell leukemia induced bya single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322(16):1117-1121. (Pubitemid 20149529)
66. Portillo J, Martin B, Hernandez R, Correas M, Gutierrez J, Del Valle J, Roca A, Vega A, Villanueva A, Gutierrez R. 1997. Results at 43 months follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Urology 49(2):187-190.
67. Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU. 1984. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 310(1):15-18. (Pubitemid 14212475)
68. Qureshi YA, Karp CL, Dubovy SR. 2009. Intralesional interferon alpha-2b therapy for adnexal Kaposi sarcoma. Cornea 28(8):941-943.
69. Ramos MC, Mardegan MC, Peghini BC, Adad SJ, Michelin MA, Murta EF. 2010. Expresion of cytokines in cervical stroma in patients with high-grade cervical intraepithelial neoplasia after treatment wit intralseional interferon alpha-2b. Eur J Gynaecol 31(5):522-529.
70. Real FX, Oettgen HF, Krown SE. 1986. Kaposis sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 4(4):544-551. (Pubitemid 16117946)
71. Richtig E, Soyer HP, Posch M, Mossbacher U, Bauer P, Teban L, Svolba G, Wolf IH, Fritsch P, Zelger B, Volc-Platzer B, Gebhart W, Mischer P, Steiner A, Pachinger W, Hintner H, Gschnait F, Rappersberger K, Pilarski P, Pehamberger H; European Cooperative Adjuvant Melanoma Treatment Study Group. 2005. Prospective, randomized, multicenter, double-blind placebocontrolled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group. J Clin Oncol 23(34):8655-8663. (Pubitemid 46211508)
72. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. 2010. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28(13):2137-2143.
73. Rosenberg SA, Yang JC,White DE, Steinberg SM. 1998. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2:identification of the antigens mediating the response. Ann Surg 228(3):307-319. (Pubitemid 30191694)
74. Siebels M, Rohrmann K, Oberneder R, Stahler M, Haseke N, Beck J, Hofmann R, Kindler M, Kloepfer P, Stief C. 2010. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX (R) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 29(1):121-126.
75. Steiner A, Wolf C, Pehamberger H. 1987. Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN alpha, r-IFN gamma, and r-IFN alpha cimetidine) in disseminated malignant melanoma. J Cancer Res Clin Oncol 113(5):459-465. (Pubitemid 17134057)
76. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. 1991. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 114(7):532-538.
77. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. 1987. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69(5): 1280-1288. (Pubitemid 17085280)
78. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU. 1983. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62(3):689-692. (Pubitemid 13001704)
79. Thaler J, Gastl G, Fluckinger T, Niederwieser D, Huber H, Seewann H, Silly H, Lang A, Abbrederis C, Gadner H, and others. 1993. Treatment of chronic myelogenous leukemia with interferon alfa-2c: response rate and toxicity in a phase II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group. Semin Hematol 30(3 Suppl 3):17-19. (Pubitemid 23260991)
80. Thompson JA, Fefer A. 1987. The treatment of hairy cell leukemia with recombinant alfa interferon: a multi-institutional study. Invest New Drugs 5 Suppl:S5-S8.
81. Verma DS, Spitzer G, Gutterman JU, Zander AR, McCredie KB, Dicke KA. 1979. Human leukocyte interferon preparation blocks granulopoietic differentiation. Blood 54(6):1423-1427. (Pubitemid 10212783)
82. Vihinen PP, Hernberg M, Vuoristo MS, Tyynela K, Laukka M, Lundin J, Ivaska J, Pyrhonen S. 2010. A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon alpha2a as first line treatment in metastatic melanoma. Melanoma Res 20(4):318-325.
83. Whelan J, Patterson D, Perisoglou M, Bielack S, Marina N, Smeland S, Bernstein M. 2010. The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer 54(3):350-354.
84. Williams CK, Svet-Moldavskaya I, Vilcek J, Ohnuma T, Holland JF. 1981. Inhibitory effects of human leukocyte and fibroblast interferons on normal and chronic myelogenous leukemic granulocytic progenitor cells. Oncology 38(6):356-360. (Pubitemid 11002689)
85. Williams RF, Sims TL, Tracey L, Myers AL, Ng CY, Poppleton H, Nathwani AC, Davidoff AM. 2010. Maturation of tumor vasculature by interferon-beta disrupts the vascular niche of glioma stem cells. Anticancer Res 30(9):3301-3308.
86. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, and others. 2003. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21(16):3127-3132. (Pubitemid 46606294)